表紙
市場調査レポート

中国のオルメサルタン市場の分析

Investigation Report on China Olmesartan Market, 2010-2019

発行 China Research and Intelligence 商品コード 297275
出版日 ページ情報 英文 20 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
中国のオルメサルタン市場の分析 Investigation Report on China Olmesartan Market, 2010-2019
出版日: 2015年06月04日 ページ情報: 英文 20 Pages
概要

オルメサルタン・メドキソミルは高血圧治療薬の一つとして、米国で2002年に認証・上市され、また2006年には中国でも上市されました。中国国内には現在、2億6,600万人の高血圧患者を抱えており、中国国内の主な死因である心臓・脳血管疾患の50%が高血圧症に関係していると言われています。高血圧症向け処方薬の市場規模は9,907億人民元に達しています。そのため、オルメサルタンの潜在的な市場規模は非常に大きいと言えます。

当レポートでは、中国におけるオルメサルタンの市場について分析し、中国国内での生産高および病院向け売上高・価格の動向(過去5年間分)、企業別・投薬形態別の市場シェア、将来的な市場動向の見通し(今後5年間分)などを調査して、その結果をお届けします。

第1章 オルメサルタンの関連概念

  • 症状
  • 世界市場での販売状況

第2章 中国のオルメサルタン市場の概要

  • 特許の現状と認可状況
  • 主要メーカー
  • 市場規模

第3章 オルメサルタンの売上高の分析

  • 売上高(金額ベース)
  • 売上高(数量ベース)

第4章 主要メーカーの市場シェアの分析

  • 市場シェア(金額ベース)
  • 市場シェア(数量ベース)

第5章 剤形別の市場規模の分析

  • 剤形別の市場シェア(金額ベース)
  • 剤形別の市場シェア(数量ベース)

第6章 オルメサルタンの病院向け基準価格(企業別)

  • Shanghai Sankyo Pharmaceutical Co., Ltd.
  • Shanghai Sine Promod Pharmaceutical Co., Ltd.
  • Beijing Winsunny Pharmaceutical Co., Ltd.

第7章 主要メーカーの分析

  • Shanghai Sankyo Pharmaceutical Co., Ltd.
  • Shanghai Sine Promod Pharmaceutical Co., Ltd.
  • Beijing Winsunny Pharmaceutical Co., Ltd.

第8章 中国のオルメサルタン市場の将来展望

  • 市場規模予測
  • 競合状況予測

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 1506191

Hypertension is the most dangerous factor that leads to the occurrence and resulting death of heart disease, cerebrovascular disease and kidney disease. According to the statistics of WHO, by 2030, nearly 23.6 million around the world will die of cardiovascular disease especially heart disease and apoplexy each year.

With the change of life styles brought about by economic development, the incidence of hypertension keeps growing in China. The number of hypertension patients is estimated to be 266 million with one in five adults suffering from it. Cardia-cerebrovascular disease is the leading cause of death in China and 50% of it relate to hypertension. Therefore, the effective control of hypertension and prevention of cardia-cerebrovascular disease has become an important health concern for health care workers and the public. On the other hand, patients need long-term pharmacotherapy for hypertension is a controllable disease.

In 1991, olmesartan medoxomil was successfully developed by Sankyo Pharmaceuticals Co., Ltd and was patented in many countries. In Apr. 2002, olmesartan medoxomil was approved by FDA to enter the American market in May. It has now become the best-selling drug in the world after it succeeded in the US market.

Compared with other ARBs, olmesartan medoxomil has distinctive pharmacokinetic properties. It develops fast after entering China with annual sales rising from CNY 4448 in 2010 to CNY 99.07 million and CAGR reaching up to 204.15%. Currently, there are three manufacturers of olmesartan in Chinese market: Shanghai Sankyo Pharmaceuticals Co., Ltd, Shanghai Sine Promod Pharmaceutical Co., Ltd and Beijing Winsunny Pharmaceutical Co., Ltd, among which Shanghai Sankyo Pharmaceuticals Co., Ltd has the biggest market share of 94.45% in 2014 with sales value reaching up to CNY 93.57 million in the same year.

With the increase of the incidence of cardiovascular disease and its number of cases, the market size of olmesartan is estimated to keep expanding in the next few years.

Readers can get at least the following information through this report:

  • market size of olmesartan in China
  • major manufacturers of olmesartan in the Chinese market and their market share
  • retail price of olmesartan in China
  • market outlook of olmesartan in China

The author suggests the following groups of people purchase this report:

  • manufacturers of cardiovascular system drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Olmesartan

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Olmesartan in China

  • 2.1. Patent and Approval Status of Olmesartan in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Olmesartan in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Olmesartan in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Olmesartan in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Olmesartan in Chinese Hospitals in 2014

  • 6.1. Shanghai Sankyo Pharmaceuticals Co., Ltd (Trade Name: Benicar)
  • 6.2. Shanghai Sine Promod Pharmaceutical Co., Ltd
  • 6.3. Beijing Winsunny Pharmaceutical Co., Ltd

7. Major Manufacturers of Olmesartan in Chinese Market, 2010-2014

  • 7.1. Shanghai Sankyo Pharmaceuticals Co., Ltd
  • 7.2. Shanghai Sine Promod Pharmaceutical Co., Ltd
  • 7.3. Beijing Winsunny Pharmaceutical Co., Ltd

8. Market Outlook of Olmesartan in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Olmesartan in China
  • Chart Approval Status of Olmesartan in China
  • Chart Sales Status of Olmesartan in China, 2010-2014
  • Chart Sales Value of Olmesartan in China, 2010-2014
  • Chart Sales Value of Olmesartan in Some Regions in China, 2010-2014
  • Chart Sales Volume of Olmesartan in China, 2010-2014
  • Chart Market Size of TOP3 Manufacturers of Olmesartan for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Olmesartan Made by Shanghai Sankyo in China, 2010-2014
  • Chart Sales Value and Market Share of Olmesartan Made by Beijing Winsunny in China, 2010-2014
  • Chart Sales Value and Market Share of Olmesartan Made by Shanghai Sine Promod in China, 2010-2014
  • Chart Sales Value and Market Share of Olmesartan Tablets in China, 2010-2014
  • Chart Price of Olmesartan Made by Shanghai Sankyo Pharmaceuticals Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Olmesartan Made by Shanghai Sine Promod Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Olmesartan Made by Beijing Winsunny Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top